Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

PMID:
27199469
2.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

PMID:
27187753
3.

Pilot evaluation of ivacaftor for chronic bronchitis.

Solomon GM, Hathorne H, Liu B, Raju SV, Reeves G, Acosta EP, Dransfield MT, Rowe SM.

Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16. No abstract available.

PMID:
27185048
4.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2016 Apr 21. pii: piw017. [Epub ahead of print]

PMID:
27103489
5.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

PMID:
26582887
6.

A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis.

Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sánchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

J Pediatric Infect Dis Soc. 2016 Mar;5(1):53-62. doi: 10.1093/jpids/piv015. Epub 2015 Apr 16.

PMID:
26407253
7.

Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.

Lahiri CD, Reed-Walker K, Sheth AN, Acosta EP, Vunnava A, Ofotokun I.

J Clin Pharmacol. 2016 Apr;56(4):492-6. doi: 10.1002/jcph.612. Epub 2015 Oct 20. No abstract available.

8.

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.

Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A; P1093 Study Team.

Pediatr Infect Dis J. 2015 Nov;34(11):1207-13. doi: 10.1097/INF.0000000000000848.

PMID:
26244832
9.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

PMID:
26148204
10.

Valganciclovir for Congenital Cytomegalovirus.

Kimberlin DW, Aban I, Acosta EP.

N Engl J Med. 2015 Jun 18;372(25):2463. doi: 10.1056/NEJMc1504937. No abstract available.

11.

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

Lahiri CD, Tao S, Jiang Y, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava A, Sanford S, Ofotokun I.

AIDS. 2015 Jun 1;29(9):1113-5. doi: 10.1097/QAD.0000000000000659.

12.

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP.

J Clin Pharmacol. 2015 Jul;55(7):748-56. doi: 10.1002/jcph.493. Epub 2015 Apr 13.

13.

Valganciclovir for symptomatic congenital cytomegalovirus disease.

Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599.

14.

Helicase-primase as a target of new therapies for herpes simplex virus infections.

James SH, Larson KB, Acosta EP, Prichard MN.

Clin Pharmacol Ther. 2015 Jan;97(1):66-78. doi: 10.1002/cpt.3. Epub 2014 Nov 18. Review.

PMID:
25670384
15.

Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.

Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR.

Am J Obstet Gynecol. 2015 Jun;212(6):812.e1-6. doi: 10.1016/j.ajog.2015.01.015. Epub 2015 Jan 13.

16.

Pharmacokinetic enhancers in HIV therapeutics.

Larson KB, Wang K, Delille C, Otofokun I, Acosta EP.

Clin Pharmacokinet. 2014 Oct;53(10):865-72. doi: 10.1007/s40262-014-0167-9. Review.

PMID:
25164142
17.

Raltegravir pharmacokinetics in neonates following maternal dosing.

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.

18.

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR.

Clin Pharmacol Ther. 2014 Sep;96(3):380-9. doi: 10.1038/clpt.2014.120. Epub 2014 May 27.

PMID:
24865390
19.

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.

J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.

20.

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I.

J Clin Pharmacol. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk